Developing a multimodal therapy for glioblastoma using oncolytic virus delivering CD19 and EGFRvIII antigens and bi-specific CARs - PubMed
6 hours ago
- #Oncolytic Virus
- #Multimodal Immunotherapy
- #Glioblastoma
- Multimodal immunotherapy strategy integrates engineered immune cells with oncolytic viruses to target glioblastoma.
- Oncolytic virus delivers CD19 and EGFRvIII antigens to glioblastoma cells for effective CAR-T and CAR-NK cell targeting.
- Oncolytic virus armed with IL-15 and IL-21 enhances immune cell expansion, persistence, and cytotoxic activity.
- Combined approach improves anti-tumor efficacy by limiting immune escape and enhancing anti-tumor immunity in vitro and in vivo.
- Strategy addresses challenges like tumor heterogeneity, antigen loss, and immunosuppressive microenvironment in glioblastoma.